Aktis Oncology, Inc.NASDAQ: AKTS

Akoustis Reports First Quarter FY24 Results

· Issued by Aktis Oncology, Inc.
  • Q1 Revenue Up 26% Year-Over-Year, In-Line with Prior Guidance
  • Guiding Revenue Flat in December Quarter, then 18 to 25% Growth with Record Revenue Projected in March Quarter
  • Growth, Cost Savings Initiatives, Chips ITC Refund Support Operating Cash Flow Breakeven